Biote Corp

Biote reports Q1 2026 EPS of $0.06 (expectation $0.10) and revenue of $44.9m (expectation $46.01m), mainly impacted by a voluntary recall of bioidentical hormone pellets. Revenue fell 8.3% year over year, treatment revenues declined 13.2%, while supplements rose 19.1% thanks to e‑commerce. The stock fell 5.43% in after‑hours trading. Despite the disruption, management reaffirms the full‑year guidance of >$190m in revenue and >$38m in adjusted EBITDA and expects a recovery in the second half of the year. » Plus sur de.investing.com

Biote reported Q1 2026 earnings of $0.06 per share versus $0.10 expected and revenue of $44.9 million versus $46.01 million expected. Revenue fell 8.3% year‑on‑year, weighed down by a voluntary recall of bioidentical hormone pellets, while the supplements segment grew 19.1%. Management maintains its full‑year revenue guidance of over $190 million and expects treatment revenues to recover in the second half of the year. After the release, the stock fell 0.45% to $2.21. » Plus sur de.investing.com

Biote Corp reported Q4 2025 EPS of $0.06, missing the $0.09 estimate; revenue was $46.4 million, slightly below the expected $47.12 million. The supplement business grew 16% thanks to e‑commerce, but could not offset declines in treatment revenue and higher clinic churn. Gross margin fell due to inventory charges following a recall; the company expects treatment revenue headwinds through the first half of 2026 and growth in the supplement segment later in the year. » Plus sur de.investing.com